[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1985004170A1 - Thiazolidinedione derivatives, process for their preparation, and medicinal composition containing same - Google Patents

Thiazolidinedione derivatives, process for their preparation, and medicinal composition containing same Download PDF

Info

Publication number
WO1985004170A1
WO1985004170A1 PCT/JP1984/000117 JP8400117W WO8504170A1 WO 1985004170 A1 WO1985004170 A1 WO 1985004170A1 JP 8400117 W JP8400117 W JP 8400117W WO 8504170 A1 WO8504170 A1 WO 8504170A1
Authority
WO
WIPO (PCT)
Prior art keywords
thiazolidinedione
compound
ethoxy
acid
methyl
Prior art date
Application number
PCT/JP1984/000117
Other languages
French (fr)
Japanese (ja)
Inventor
Kanji Meguro
Takeshi Fujita
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Priority to PCT/JP1984/000117 priority Critical patent/WO1985004170A1/en
Priority to PCT/JP1984/000445 priority patent/WO1985004171A1/en
Priority to US06/711,536 priority patent/US4582839A/en
Priority to JP60041584A priority patent/JPS60208980A/en
Priority to EP85301895A priority patent/EP0155845A1/en
Priority to CA000476976A priority patent/CA1263961A/en
Publication of WO1985004170A1 publication Critical patent/WO1985004170A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • Thiazolidinedione tsuba conductor method for producing the same, and pharmaceutical composition containing the same
  • the present invention relates to a novel thiazolidinedione derivative having excellent blood sugar and blood lipid lowering effects, a method for producing the same, and a pharmaceutical composition comprising the same.
  • ⁇ Holeurea compounds are used.
  • biguanide compounds cause lactic acidosis and are therefore rarely used at present, and phororerea compounds have potent hypoglycemic activity, but often cause severe hypoglycemia. , Care must be taken in use.
  • the present inventors have found a novel thiazolidinedione derivative having an excellent blood serum and blood lipid lowering action.
  • the present invention is a.
  • H 1 and !! 2 are the same or different and represent hydrogen or a lower alkyl group
  • R 3 represents hydrogen or an acyl group
  • n represents 0 or 1.
  • R 1 , !! 2 and n have the same meanings as above.
  • R 4 is hydrogen or a group
  • R 5 is hydrogen or a lower group
  • X is a halogen atom
  • n is n Indicates 0 or 1, respectively. Is reacted with thiourea to give
  • a — a pharmaceutical composition comprising a thiazolidine conductor represented by formula (I) or a salt thereof,
  • Formula (I), (2) and (Summer) Medium Rl as the low-Hi key group represented by R 2, for example methylcarbamoyl, E Ji, Burobi, I, knobs port bi, butyrate etc. carbon atoms 1 Among them, those having 4 to 3 carbon atoms are preferred, and those having 1 to 3 carbon atoms are preferable, and these may be substituted at any position of the pyridine ring.
  • Examples of the acyl group represented by R 3 include, for example,
  • O PI ⁇ There are 1 to 8 carbon ash groups such as dibutyl, brobion! /, Butyric, isobutyryl, penzoi W, and toy *.
  • Examples of the ash group represented by R 4 include the same as the ash group represented by.
  • Examples of the lower aki group represented by R 1 include the same as the lower aki group represented by R 1 .
  • Examples of the halogen atom represented by 3C include chlorine, bromine and iodine.
  • the four thiazolidinedione compounds represented by the formula (I) are amphoteric compounds having an acidic nitrogen in the thiazolidine ring and a basic nitrogen in the viridine ⁇ , and have both ⁇ salt and base ⁇ .
  • the boundary of the thiazolidinedione conductor (I) is as a salt such as hydrochloride, hydrogen bromide completion, sulfuric acid, phosphoric acid, methansulfone, etc.
  • Organic plants such as acid salts, salt, malt salt, maleic acid, fumanore salt, succinic acid, tartaric acid, malic acid, etc.
  • Metal salts such as lithium salt, aluminum-palladium salt, magnesium salt, and casium are listed.
  • thiazolidinedione-conductor represented by formula (I) according to the present invention and the thiazolidinedione-conductor include the following compounds.
  • the reaction between the compound represented by the general formula () and thiourea is usually carried out with a class of alcohols (eg, methanoic, ethano, * ropano; W, 2-propanol, butano, isobbutano; u, 2-methyl) It is carried out in any solvent such as toki ⁇ ethanol, dimethyl sulphoxide and suholane.
  • the degree of reversal is usually 2 to 180, preferably 60 to 150.
  • the amount of thiourea used is 1-2 mol per 1 mol of the compound (S). In this reaction, hydrogen halide is by-produced with the progress of the reaction.
  • a dehydrating agent such as sodium phosphate or potassium acetate may be added to carry out the reaction.
  • the acid stabilizer is generally used in an amount of 1 to 1.5 moles per mole of the compound (H).
  • Such anti-FS! The compound (an is produced and, if desired, can be isolated; however, the compound may be directly led to the next hydrolysis step without (().
  • the hydrolysis of the compound ( ⁇ ) is usually performed in a suitable solvent in the presence of water and a mineral acid.
  • the solvent include those used for the reaction between the compound (2) and thiourea.
  • the mineral acid include hydrochloric acid, hydrobromic acid, sulfuric acid and the like.
  • the amount of the mineral acid to be used is ⁇ 1 to 10 mol, preferably ⁇ 12 to 3 mol per mol of the compound ().
  • the amount of water to be added depends on compound (I) It is usually a large surplus for l. This reaction is usually performed under heating or heating.
  • the reaction temperature is usually 60 to 150 watts.
  • the heating time is usually several hours to over ten hours.
  • the hydroxy form (]) may be subjected to the following Aich reaction as necessary.
  • the acylation reaction of the hydroxyl form () is usually carried out by reacting an acylating agent in an appropriate solvent in the presence of a 3 ⁇ 4 group.
  • the solvent include yeast esters, esthetics, for example, aromatic hydrocarbons such as benzene, toluene, and xylene, and ethers, such as acetic acid, diisobromo, etc./ether, tetrahydrofuran, and dioxane.
  • ketones such as acetone and methetic ketone-such as dichloromethane, chloromethane, carbon tetrachloride, chlorinated hydrocarbons, and dimethyformamide.
  • the facilitating agent include gi, g, umami, araliphatic, and aromatic sai anhydrides and halides.
  • the aliphatic power is, for example, vinegar ⁇ , brobion.
  • Carbon such as ,, ⁇ acid, iso ⁇ ⁇ , completed Yoshikusa, completed Iso Yoshikusa, hexane ⁇
  • the aromatic aromatic carbons are, for example, charcoal cords 8 to 9 such as Hua-vinegar sai and the ferrocarbons, and the aromatic carbons are, for example, benzoic acid, Paramethyi benzoic acid such as those having 7 to 8 carbon atoms, and further on these aromatic rings, for example, halogens (eg, fluorene, chlorine, bromine, etc.), akoxy (eg, methoxy, ethoxy, etc.) , Trifluoromethyl group and the like may be substituted.
  • halogens eg, fluorene, chlorine, bromine, etc.
  • akoxy eg, methoxy, ethoxy, etc.
  • Trifluoromethyl group and the like may be substituted.
  • the amount of the acylating agent to be used is usually 1 to 1 mol of the hydroxy form (I '). 10 3 ⁇ 4 ⁇ Preferably, it is 1-2.
  • the azo group include viridin and thietamine, such as, for example, sodium carbonate * potassium carbonate * sodium bicarbonate, potassium hydrogen carbonate, carbonic acid, and hydrogen peroxide.
  • the base is usually used in an equimolar amount or in excess of the acylated compound.
  • pyridine When pyridine is used as the group, a large excess amount of pyridine is used.] It can also serve as a solvent. This reaction is generally carried out at a temperature of from 20 t to 40, and the reaction time is usually from 10 minutes to 24 hours.
  • a compound in which R 3 is an ash group in the killing formula (I) [may also be referred to as a lower alcohol form ((')] can be obtained.
  • the thiazolidinedione derivative (I) is necessary]. It can also be reacted with an acid or a sulfonic group according to a conventional method and led to the boundary.
  • the thiazolidinedione thus obtained and the thiazolidinedione are obtained by known means of separation and purification, for example, by using concentrated pestle, is, solvent extraction, crystallization, recrystallization, dissolution, chromatography and the like. can do.
  • thiazolidinedione hypoconductor (I) and its salt are useful for treating hyperlipidemia and diabetes in humans and their complications.
  • the method of administration is usually orally used, for example, as pills, capsules, powders, granules, etc., but in some cases it can be given non-periodically as injections, suppositories, or pellets.
  • ⁇ ⁇ 5 J ⁇ i ⁇ is usually administered orally (X 0 1 -1 o ⁇ z ⁇ 3 ⁇ 4 parenterally, or lipolipidemic) per adult per day.
  • ⁇ 55 to 10 When used as an agent for the treatment of infectious diseases, ⁇ 55 to 10 can be administered orally and ⁇ ⁇ to i ⁇ 3 ⁇ 4? ⁇ ⁇ can be administered non-radially per adult per day. It is desirable to administer this amount once a day or two to four times a week.
  • the starting compound ( ⁇ ) of the present invention can be produced, for example, by the following method.
  • R 1, R 2 and X are as defined above der]
  • the oxidation reaction of compound (W) to compound (V) is achieved by reacting compound (IV) with hydrogen peroxide or an organic peracid! ? Can be easily done.
  • organic peracids include, for example, formic acid, peroxide, pertriprostatic, perbenzoic acid, m-chloroperbenzoic acid, and the like. It can be performed according to the method.
  • the assimilation reaction from (V) to chemical ⁇ 5 (IT) is achieved by reacting the chemical with ⁇ J (V)!
  • the reaction is usually performed with anhydrous or halide
  • the hydrolysis reaction from compound (H) to compound (IT) can be performed by a usual method using sodium hydroxide or potassium hydroxide.
  • reaction from compound (w) to compound (W) is achieved by combining compound (g) with compound 01> in the presence of sodium hydride! ) Done.
  • This reaction can be carried out at a temperature of 10 t to 20 watts in a solution of dimethiformamide, titro- drofuran, or the like.
  • the reaction from the compound (3 ⁇ 4!) To the compound () is carried out by catalytic reduction of the compound (W) using, for example, palladium carbon as a catalyst in a conventional manner.
  • compound () is diazotized in the presence of hydrogen halide.
  • HX acrylic acid or its esthetics
  • a copper catalyst eg, oxidative oxidation
  • the reaction is carried out under the condition of copper, copper oxide, copper chloride, cupric chloride, ferrous bromide, cupric bromide, etc.
  • the reaction from the compound ⁇ ( ⁇ ) to the compound (3T) is performed by converting the compound 3 ⁇ 48 (IT) into a compound. This reaction can be carried out in the same manner as in the method for converting the compound (V) into a compound.
  • kink Gin (1 0, poured into water was stirred for 8 hours a mixture of anhydrous ⁇ (0.1 at room temperature, and extracted with ⁇ acid Echiru. Gun ⁇ E Chi layer was washed with water, dried (MgSO 4) the solvent And the residue is removed
  • mice Hypoglycemic and lipid-lowering effects in mice
  • the test compound was mixed with powdered feed (CE-2, CLEA Japan) (005%) and freely mixed with KKA mice (male, 8-: L0 week old, 15 mice). Water was given ad libitum during this period, blood was collected from the bacterium, blood was collected by the glucose assay, and plasma triglyceride levels were determined by the fistula method! By using Cleantech TG-S kit (Chatron)]. Each value was shown as a reduction rate () with respect to the drug non-administration group.
  • Compound Hypoglycemic action Lipid-lowering action
  • novel thiazolidinedione derivative (I) according to the present invention has an excellent blood and blood lipid-returning effect, and is useful as a pharmaceutical such as a therapeutic agent for diuresis and a therapeutic agent for hyperlipidemia.

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Thiazolidinedione derivatives represented by general formula (I), wherein R1 and R2 may be the same or different and each represents hydrogen or lower alkyl, R3 represents hydrogen or acyl, and n represents 0 or 1, and their salts are novel compounds showing an effect of lowering blood sugar level and blood lipid level, and are useful as agents for treating diabetes and hyperlipemia.

Description

明 細 害  Harm
チアゾリジンジオン鍔導体,その製造法 よび それを含んで る¾薬組成物  Thiazolidinedione tsuba conductor, method for producing the same, and pharmaceutical composition containing the same
技 術 分 野  Technical field
本発明は血糖及び血中脂質泜下作用を優する新規チアゾリジンジオン 誘導体,その製造法およびそれを含んでなる医薬組成物に関する。  TECHNICAL FIELD The present invention relates to a novel thiazolidinedione derivative having excellent blood sugar and blood lipid lowering effects, a method for producing the same, and a pharmaceutical composition comprising the same.
背 _^ _ ¾ _  Back _ ^ _ ¾ _
従来よ 、糖尿病治療剤として種々のビグアナィド系化合物およびス Conventionally, various biguanide compounds and salts have been used as therapeutic agents for diabetes.
Λホ-ルウレァ系化合物が用 られている。 しかし、 ビグアナイド系化 合物は乳酸ァシドーシスを引き起こすため、現在ほとんど用 られてお らず、 またス ホ -ルゥレア系化合物は強力 ¾血溏低下作用を有するが しばしば重篤な低血糖を引き起し、使用上の注意が必要である。 本発明 者らはこのよう 欠点のない血糖低下作用を有する化合物を見いだすべ く種々研究の結果、 優れた血锩及び血中脂質低下作用を有する新規チア ゾリジンジォン誘導体を見いだした。 ΛHoleurea compounds are used. However, biguanide compounds cause lactic acidosis and are therefore rarely used at present, and phororerea compounds have potent hypoglycemic activity, but often cause severe hypoglycemia. , Care must be taken in use. As a result of various studies to find a compound having a blood glucose lowering action without such a defect, the present inventors have found a novel thiazolidinedione derivative having an excellent blood serum and blood lipid lowering action.
発 明 の 闢 :  The Age of Discovery:
本発明は、  The present invention
L —般式  L — general formula
Figure imgf000003_0001
Figure imgf000003_0001
〔式中、 H1 , !!2は同一または異なって水素または低級ア キ 基を、 R3 は水素またはァシ 基を、 nは 0または 1を示す。 〕で表わされる チアゾリ ジンジオン誘導体、 [In the formula, H 1 and !! 2 are the same or different and represent hydrogen or a lower alkyl group, R 3 represents hydrogen or an acyl group, and n represents 0 or 1. A thiazolidinedione derivative represented by the formula:
 ,
OMPI OMPI
?o 2. —般式 ? o 2. —General formula
( I ) (I)
(CH2)n X (CH 2 ) n X
t  t
OR4 OR 4
〔式中、 R1 , !!2および nは前記と同意義であ ] R4 は水素またはァ 、ン 基を、 R5 は水素または低級ア キ 基を、 Xはハロゲン原子を、 nは 0または 1をそれぞれ示す。 〕で表わされる化合物とチォ尿素とを 反応させて一 S¾ Wherein R 1 , !! 2 and n have the same meanings as above. R 4 is hydrogen or a group, R 5 is hydrogen or a lower group, X is a halogen atom, and n is n Indicates 0 or 1, respectively. Is reacted with thiourea to give
Figure imgf000004_0001
Figure imgf000004_0001
〔式中の各記号は前記と同意義である。 〕で表わされる化合物を得、つ でこれを 3P水分解し、必要によ J?さらにァシ 化することを特徼とす る一教式( I )で表わされるチアゾリジンジオン誘導体の製造法、 および  [Each symbol in the formula is as defined above. A method for producing a thiazolidinedione derivative represented by the formula (I), which is characterized in that the compound represented by the formula and
a — ¾式( I )で表わされるチアゾリジン 導体またはその塩を含ん でなる医薬組成物、 a — a pharmaceutical composition comprising a thiazolidine conductor represented by formula (I) or a salt thereof,
に闋するものである。 It is something to do.
前記一般式( I ) , ( 2 )および(夏)中 Rl , R2で示される低殺ァ キ 基としては、 例えばメチ ,ェチ ,ブロビ ,ィ、ノブ口ビ , ブチ ど炭素数 1〜 4のものがあげられるが、 なかでも炭素数 1〜 3 のものが好ましく、 これらはビリジン環の任意の位置に置換して ても よ 。 R3 で示されるァシル基としては例えばホ ミ 、たとえばァセ Formula (I), (2) and (Summer) Medium Rl, as the low-Hi key group represented by R 2, for example methylcarbamoyl, E Ji, Burobi, I, knobs port bi, butyrate etc. carbon atoms 1 Among them, those having 4 to 3 carbon atoms are preferred, and those having 1 to 3 carbon atoms are preferable, and these may be substituted at any position of the pyridine ring. Examples of the acyl group represented by R 3 include, for example,
O PI ― チ Λ , ブロビォ二 !/, ブチリ , イソブチリル , ペンゾィ W , ト オイ *ど炭素数 1〜8のァシ 基があげられる。 R4 で示されるァシ 基 としては で示されるァシ 基と同様 ものがあげられる。 で示 される低級ア キ 基としては前記 R1 , で示される低級ァ キ 基 と同様なものがあげられる。 また 3Cで示されるハロゲン原子としてはた とえば塩素,臭素,ヨウ素があげられる。 O PI ― There are 1 to 8 carbon ash groups such as dibutyl, brobion! /, Butyric, isobutyryl, penzoi W, and toy *. Examples of the ash group represented by R 4 include the same as the ash group represented by. Examples of the lower aki group represented by R 1 include the same as the lower aki group represented by R 1 . Examples of the halogen atom represented by 3C include chlorine, bromine and iodine.
—被式( I )で表わされるチアゾリジンジオン 4体はそのチアゾリ ジン環に酸性窒素を、 またビリ ジン璨に塩基性窒素を有する両性化合物 であ 、黢塩および塩基壎の双方が存在する。 チアゾリジンジオン 導 体( I )の境としては、綾塩としてたとえば、 塩酸塩,臭化水素竣氇, 硫綾氇, ん酸 ¾ , メタ ンスルホン^ ¾などの墚機酸 ¾、たとえばトル ェンス 1 ホン酸塩, シユウ^塩, マ口ン 塩, マレイン鲮壎, フマーノレ 翁塩 ,ュハク酸渲,酒石酸瘇, リンゴ酸氇などの有璣 植が、壎基 ¾と してはたとえばナト リウム塩,カ リ ウム塩,アルミ -ゥム塩,マグネシ ゥム塩,カ シウム どの金属塩がそれぞれあげられる。  —The four thiazolidinedione compounds represented by the formula (I) are amphoteric compounds having an acidic nitrogen in the thiazolidine ring and a basic nitrogen in the viridine 黢, and have both {salt and base}. The boundary of the thiazolidinedione conductor (I) is as a salt such as hydrochloride, hydrogen bromide completion, sulfuric acid, phosphoric acid, methansulfone, etc. Organic plants such as acid salts, salt, malt salt, maleic acid, fumanore salt, succinic acid, tartaric acid, malic acid, etc. Metal salts such as lithium salt, aluminum-palladium salt, magnesium salt, and casium are listed.
本発明に係る一被式( I )で表わされるチアゾリジンジオン^導体お よびその壚の具体例としては例えばつぎの化合物があげられる。  Specific examples of the thiazolidinedione-conductor represented by formula (I) according to the present invention and the thiazolidinedione-conductor include the following compounds.
5一 { 4一〔 2—ヒ ドロキシー 2—( 5—メチ 一 2一ビリ ジ )ェ トキシ〕ベンジ }一 2 , 4一チアゾリ ジンジォン  5-1 {4-1-1 [2-hydroxy 2- (5-methyl-2-bi) ethoxy] benzy} 1-2,4-thiazolidine
5— { 4一 〔 2—ァセ トキシー 2—( 5 —メチ 一 2—ピリ ジ )ェ トキシ〕ペンジ }一 2 , 4—チアゾリ ジンジオン  5— {4- [2-acetoxy 2- (5-methyl-2-pyridy) ethoxy] penti} -1,4-thiazolidinedione
5— { 4一〔 3— ドロキシー 2— ( 3—メチ 一 2—ビリ ジ ) 7* ロポキシ〕ペンジ }一 2 , 4—チアゾリ ジンヅ才ン  5— {4- (3-droxy 2- (3-meth-1-2-bilge) 7 * ropoxy) pent}}-1,4-thiazolidin
5— { 4一〔 3—ァセ トキ ー 2—( 3—メチ 一 2—ビリ ジ )ブ 口ポキ Ίペンジ〃 }一 2 , 4一チアゾリ ジンジオン  5— {4- (3-acetoxy 2 -— (3-meth-1-2-bilge)) lip-opening {penzi}} 1,2,4-thiazolidinedione
' 5— { 4一〔 3—ペ ゾィ ォキ 一 2— ( 3一メチ 一 2—ビリジ ル)ブロボキ 〕ベンジ; — 2 , 4—チアダリジンジオン ' 5— {4-I- (3-Pezo-Ioki 2 -— (3-Methyl-I-2-Bidyl) Broboki) Benzi; —2,4-Thiadaridinedione
5— { 4一〔 2—( 5—ェチ 一 2一ビリ ジ )一 2—ヒドロキ ェ トキ 〕ペンジ }一 2 , 4—チアゾリ ジンジオン  5— {4- [2- (5-ethyl-1-2-1) 1-2-hydroxy] pent}} 2,4-thiazolidinedione
5— { 4一〔 2—( 5—ェチ 一 2—ビリ ジ )一 2—ホ ミ 才キ シエ トキシ〕ペンジ u}— 2 , 4—チアゾリ ジンジオン  5— {4—1—2— (5—1—2—bilidine) 1—2—Hydroxy pentoxy u) —2,4—Thiazolyzindione
5— { 4一〔 2—ァセ トキシー 2 - ( 5一ェチ; — 2一ビリ ジ )ェ トキシ〕ベンジ; } — 2 , 4—チアゾリ ジンジ才 V  5— {4- (2-acetoxy 2-(5-eth); —2-bi) ethoxy) benzy;} — 2,4-thiazoli
5— { 4一〔 2—( 5—ェチ 一 2—ビリ ジ )一 2—ブロビォ - 才キシエトキシ〕ペンジ )一 2 , 4一チアゾリジンジオン  5- (4- (2- (5-Et-1-2-bi) -1) 2-Brovio-pyroxyethoxy) penti) 1-2,4-Thiazolidinedione
5— { 4一〔 2—( 5ー チ ー 2一ビリ ジ ) 一 2—ブチリ ォキ シェトキ 〕ペンジ }一 2 , 4—チアゾリ ジンジォン  5— {4—1—2— (5—2 × 1) 1—2—Butyloki Shetki) Peng} 1—2,4—Thiazoli
5— { 4一〔 2—( 5—ェチ 一 2—ビリ ジ )一 2—イソブチリル ォキシエトキシ〕ペンジ Λ }― 2 , 4一チアゾリ ジンジオン  5— {4-1 (2- (5-ethyl-2-bi) -1) -2-isobutyryloxyethoxy] pent Λ} —2,4-thiazolidinedione
5— { 4一〔 2— ( 5—ェチ 一 2—ピリ ジ〃)一 2—ノ レリ ォキ シェトキシ〕ペンジ } - 2 , 4一チアゾリ ジンジ才ン  5— {4- (2- (5-ethyl-1-2-pyridyl) -1-2-norreloxy shetoxy) pent}-2,4,1-thiazoli
5— { 4一〔 2—べンゾィ ォキシ一 2—( 5—ェチ 一 2—ビリ ジ ル)エトキシ〕ペンジ }一 2 , 4—チアゾリジンジオン  5- {4- [2-benzoxy-1-2- (5-ethyl-1-bibenzyl) ethoxy] penti} -1,2,4-thiazolidinedione
5— { 4一〔 2—( 5—ェチ 一 2—ビリ ヅル)一 3—ヒ ドロキシブ ロボキシ〕ペンジ }一 2 , 4—チアゾリ ジンジォン  5— {4—1—2— (5—1—2—bilyl) 1—3—Hydroxybloboxy} peng} 1—2,4—Thiazolyzindione
5— { 4一〔 3—ァセ トキシー 2—( 5—ェチルー 2—ビリジ )ブ ポキシ〕ベンジル }一 2, 4一チアゾリ ジンジオン  5- {4- [3-acetoxy-2- (5-ethyl-2-viridyl) buoxy] benzyl} -1,2-thiazolidinedione
5一 { 4一〔 2ーヒド Pキシー 2— ( 2—ビリ ジ )エトキシ〕ペン ジ }一 2 , 4一チアゾリジンジォン  5-1 {4-1 [2-Hydroxy Pxy 2— (2-Bridge) ethoxy] pent} 1, 2, 4 Thiazolidinedione
5— { 4一〔 2 -ァセ トキシー 2—( 2一ピリジ )ェトキシ〕ペン ジ/ « }— 2 , 4—チアゾリ ジンジ才ン 5— {4- (2-acetoxy 2 -— (2-pyridy) ethoxy) pen Di / «} — 2,4—thiazoli
5— { 4一〔 2—ブロビ才 -ルォキシー 2—( 2—ビリ ジ )ェトキ ^〕べンジ }ー2 » 4—チアゾリジンジオン  5— {4- (2-Brobi-Roxy 2— (2-Bilizy) etoki ^] Benzy} -2 »4-Thiazolidinedione
5— { 4一〔 2—ベンゾィ ォキシ一 2— ( 2—ビリ ジ )エ トキシ 〕ぺンジ;u }— 2 , 4—チアゾリ ジンジオン  5- {4- [2-benzoxy-1- (2- (2-bi) oxy) ethoxy] benzene; u} —2,4-thiazolidinedione
5— { 4一〔 3—ヒ ドロキシー 2—( 2—ビリ ジ ) ブロ キシ〕ベ ンジ } - 2 , 4一チアゾリ ジンジオン  5- {4- [3-hydroxy 2- (2-biloxy) oxy] benzene}-2,4-thiazolidinedione
5一 { 4一〔 3—ァセ トキシー 2— ( 2—ビリジ )ブロ キシ〕ベ ンジル }一 2 , 4一チアゾリ ジンジォン  5-1 {4- [3-acetoxy 2- (2-viridyl) oxy] benzyl} 1-2,4-thiazolidindione
5一 { 4一〔 2—ヒ ドロキシー 2— ( 5—メチルー 2—ビリジ )ェ トキシ〕ベンジ u}— 2 , 4—チアゾリ ジンジオン  5-1 {4-1 (2-Hydroxy-2- (5-methyl-2-viridyl) ethoxy) benzyu} —2,4-thiazolidinedione
5 - { 4 - C 2 -ァセ トキシー 2—( 5—メチノレー 2—ビリジ )ェ トキシ〕ぺンジ } - 2 , 4一チアゾリ ジンジ才ン  5-{4-C 2 -acetoxy 2-(5-methinolate 2-bilge) ethoxy] benzene}-2,4-thiazoli
5— { 4一〔 2—( 5—メチ ー 2—ピリジ )一 2—ブロビ才 - 才キシエ トキシ〕ペンジ } — 2 , 4—チアゾリ ジンジオン  5— {4- (2- (5-methyl-2-pyridyl) 1-2-blovi-old-year-old ethoxyethoxy) pent}} — 2,4-thiazolidinedione
5— { 4一〔 2—べンゾィ 才キシー 2—( 5一メチ 一 2—ピリ ジ )エトキシ〕ぺンジ/ ! } - 2 , 4一チアゾリ ジンジ才ン  5— {4- (2-benzoxy) 2 -— (5-methyl-2-pyridyl) ethoxy] benzene /!}-2,4,1-thiazolidine
5— { 4一〔 3—ヒ ドロキシー 2—( 5—メチ 一 2—ビリジル ) ブ ロポキシ〕ベンジ }一 2 , 4—チアゾリ ジンジ才ン  5- {4- [3-hydroxy-2- (5-methyl-2-viridyl) propoxy] benzy} -1,2,4-thiazoli
5— { 4一〔 2—ヒ ドロキシー 2— ( 3—メチ 一 2—ビリジル)ェ トキシ〕ペンジル }一 2 , 4一チアゾリ ヅンジオン  5— {4- [2-hydroxy-2- (3-methyl-2-viridyl) ethoxy] penzil} -1,2,4-thiazolidinedione
5— { 4一〔 2—ァセ トキシ一 2- ( 3—メチ 一 2—ビリ ジ )ェ トキシ〕ペンジル }一 2 , 4一チアゾリ ジンジ才ン  5— {4- (2-acetoxy-1- (3-methyl-2-bis) ethoxy) penzil} —1,2,4-thiazolidine
5— { 4一 〔 2—ベンゾィ ォキシ一 2—( 3—メチ 一 2—ビリジ )エ トキシ〕ベンジ }一 2 , 4—チアゾリ ジンジ才ン 5— { 4一〔 2— ドロキシー 2—( 4ーメチ 一 2—ビリ ジ )ェ トキシ〕ペンジ }一 2 · 4—チアゾリ ジンジオン 5— {4—1—2-Benoxy-1—2- (3-Methyl-2-vizi) ethoxy) benzy} —1,2,4-Thiazoli 5— {4- [2-droxy 2- (4-meth-1-2-viridyl) ethoxy] pent]} 2-4-thiazolidinedione
5— { 4一〔 2—ァセ トキシー 2—( 4一メチ 一 2—ビリ ジル〉ェ トキシ〕ペンジ }— 2, 4一チアゾリ ジンジオン  5— {4- (2-Acetoxy 2 -— (4-Meth-1-2-Byryl> ethoxy) pent)} — 2,4-Triazolidinedione
5— { 4一〔 2—ヒ ドロキシー 2— ( 4 , 6—ジメチ 一 2—ビリジ )エトキ 〕ペンジ A }— 2 , 4—チアゾリ ジンジォン  5— {4- [2-hydroxy-2- (4,6-dimethy1-2-viridyl) ethoxy] Penzi A} —2,4-thiazolidindione
5— { 4 - 2—ァセトキシー 2—( 4 , 6—ジメチ 一 2—ビリジ ル)エトキシ〕ペンジ }一 2, 4一チアゾリ ジンジオン  5— {4-2-acetoxy 2 -— (4,6-dimethy1-2-viridyl) ethoxy] penti} —1,2,4-thiazolidinedione
一般式( )で表わされる化合物とチォ尿素との反応は、通常ア コ 一 類 (例、 メタノ一 ,エタノー , *ロパノー; W , 2—プロパノ一 ル, ブタノー , ィソブタノ一; u , 2—メ トキ^エタノー 等) , ジメ チ ス ホキシド,ス ホラン どの溶媒中で行なわれる。 反 溘度は 通常 2ひ 一 1 8 0 ,好ましくは 6 0 一 1 5 0 である。 チォ尿素 の使用量は化合物( S ) 1モ に対し 1〜2モルである。本反応に ^ ては反応の進行に伴ないハロゲン化水素が副生するが、 これを捅拔する ため齚酸ナト リウム ,酢酸力リウム どの脱缀剤を加えて反応を行なつ てもよ 。 说酸剤は化合物 ( H ) 1 ¾ルに対し通常 1〜: 1. 5モ 用いら れる。 このような反 fSによ!?化合物( anが生成し、所望によ これを 単離することもで Aるが、 ( ΙΪ )を単 することなく直ちにつぎの加水 分解工程に導びいてもよい。  The reaction between the compound represented by the general formula () and thiourea is usually carried out with a class of alcohols (eg, methanoic, ethano, * ropano; W, 2-propanol, butano, isobbutano; u, 2-methyl) It is carried out in any solvent such as toki ^ ethanol, dimethyl sulphoxide and suholane. The degree of reversal is usually 2 to 180, preferably 60 to 150. The amount of thiourea used is 1-2 mol per 1 mol of the compound (S). In this reaction, hydrogen halide is by-produced with the progress of the reaction. To remove this, a dehydrating agent such as sodium phosphate or potassium acetate may be added to carry out the reaction. The acid stabilizer is generally used in an amount of 1 to 1.5 moles per mole of the compound (H). Such anti-FS! The compound (an is produced and, if desired, can be isolated; however, the compound may be directly led to the next hydrolysis step without (().
化合物 ( π )の加水分解は、通常適当な溶媒中水および鉱酸の存在下 に行 ¾われる。溶媒としては前記化合物( 2 )とチォ尿素との反応に用 られる溶媒があげられる。鉱酸としてはえとえば塩酸,臭化水素酸, 硫綾 どがあげられ、その使用量は化合物 ( ) 1モ に対し α 1〜 1 0モ 、好ましくは <1 2〜 3 〃である。 水の添加量は化合物( I ) lモ に対し通常大遢剰量である。本反応は通常加温または加熱下に行The hydrolysis of the compound (π) is usually performed in a suitable solvent in the presence of water and a mineral acid. Examples of the solvent include those used for the reaction between the compound (2) and thiourea. Examples of the mineral acid include hydrochloric acid, hydrobromic acid, sulfuric acid and the like. The amount of the mineral acid to be used is α1 to 10 mol, preferably <12 to 3 mol per mol of the compound (). The amount of water to be added depends on compound (I) It is usually a large surplus for l. This reaction is usually performed under heating or heating.
¾われ反応温度は通常 6 0〜 1 5 0わである。 加熱時間は通常数時間〜 十数時間である。 The reaction temperature is usually 60 to 150 watts. The heating time is usually several hours to over ten hours.
本反応によ D—殺式( I )中 Rs が水素である化合物〔 下ヒ ドロキ シル体( Γ )ということもある〕を得ることができる。. According to this reaction, a compound in which R s in D-killing formula (I) is hydrogen [may be referred to as a lower hydroxy compound (Γ)] can be obtained. .
前記ヒ ドロキシ 体( ] )は必要によ]つぎのア ^ ィヒ反応に付して もよい。  The hydroxy form (]) may be subjected to the following Aich reaction as necessary.
ヒドロキシル体( )のァシ 化反応は通常適当な溶媒中 ¾基の存在 下ァシ 化剤を作用させることによ j?行なわれる。 該溶媒としてはたと えば酵羧ェチル ¾どのエステ 類、 たとえばベンゼン , ト エン ,キ^ レンなどの芳香挨炭化水素類、 たとえばジェチ エーテ ,ジイソブロ ビ》 /ヱーチ , テトラヒ ドロフラン , ジォキサンなどのエーテル類、た とえばァセ ト ン , メチ ェチ ケト ンなどのケ ト ン類-、 たとえばジクロ ルメタン ,クロ口ホ ム ,四氇化炭素 どの塩素化炭化水素類の他ジメ チ ホ ムアミ ドなどがあげられる。 ァシ 化剤としてはギ ,, g旨肪族 ,芳香脂肪族または芳香族力 ボン鲮の釵無水物または ハヲイドなど があげられる。 該脂肪族力 ボン燄としてはたとえば酢^ ,ブロビオン The acylation reaction of the hydroxyl form () is usually carried out by reacting an acylating agent in an appropriate solvent in the presence of a ¾ group. Examples of the solvent include yeast esters, esthetics, for example, aromatic hydrocarbons such as benzene, toluene, and xylene, and ethers, such as acetic acid, diisobromo, etc./ether, tetrahydrofuran, and dioxane. For example, ketones such as acetone and methetic ketone-such as dichloromethane, chloromethane, carbon tetrachloride, chlorinated hydrocarbons, and dimethyformamide. Can be Examples of the facilitating agent include gi, g, umami, araliphatic, and aromatic sai anhydrides and halides. The aliphatic power is, for example, vinegar ^, brobion.
■ ,^酸, イソ^醆,吉草竣, ィソ吉草竣,へキサン^など炭素 c 2〜■ Carbon, such as ,, ^ acid, iso ^ 醆, completed Yoshikusa, completed Iso Yoshikusa, hexane ^
6のものが、該芳香脂肪族力 ボン としては例えばフエ- 酢釵,フ ェ- ブロビ才ン鲮など炭索敛 8〜9のものが、 また該芳香族力 ボン 酸としてはたとえば安息香^ ,パラメチ 息香酸 ¾ど炭素数 7〜 8の ものがあげられ、 さらにこれら芳香環上には例えばハロゲン(例、 フプ 素,塩素,臭素など) , ア コキシ(例、 メ トキシ , エトキシなど) , トリフ ォロメチ〃基などが置換していてもよい。 6, the aromatic aromatic carbons are, for example, charcoal cords 8 to 9 such as Hua-vinegar sai and the ferrocarbons, and the aromatic carbons are, for example, benzoic acid, Paramethyi benzoic acid such as those having 7 to 8 carbon atoms, and further on these aromatic rings, for example, halogens (eg, fluorene, chlorine, bromine, etc.), akoxy (eg, methoxy, ethoxy, etc.) , Trifluoromethyl group and the like may be substituted.
ァシル化剤の使用量はヒ ドロキシ 体( I' ) 1モルに対し通常 1〜 1 0 ¾ Λ 好ましくは 1〜 2 である。壌基としてはたとえばビリジ ン, ト Uェチ ァミン¾どのァミン類、たとえば炭酸ナトリウム *炭酸 カリウム *炭酸水素ナトリウム ,炭酸水素力 リウム¾ど炭酸 ¾,重 酸 瘙などがあげられる。塩基は通常ァシ 化 ¾と等モ 量または過瘸量用 いられる。壎基としてビリ ジンを用いる場合はビリジンの大過常量を用 ることによ]?溶媒を兼ねることができる。 本反応は通常一 2 0 t〜 4 0 で行なわれ、反応時間は通常 1 0分〜 2 4時 Mである。 この反 iS によ]?—殺式( I )中 R3 がァシ 基である化合物〔 下ァ ^ル体(ェ') とい こともある〕を得ることができる。 The amount of the acylating agent to be used is usually 1 to 1 mol of the hydroxy form (I '). 10 ¾ Λ Preferably, it is 1-2. Examples of the azo group include viridin and thietamine, such as, for example, sodium carbonate * potassium carbonate * sodium bicarbonate, potassium hydrogen carbonate, carbonic acid, and hydrogen peroxide. The base is usually used in an equimolar amount or in excess of the acylated compound. (4) When pyridine is used as the group, a large excess amount of pyridine is used.] It can also serve as a solvent. This reaction is generally carried out at a temperature of from 20 t to 40, and the reaction time is usually from 10 minutes to 24 hours. According to this anti-IS, a compound in which R 3 is an ash group in the killing formula (I) [may also be referred to as a lower alcohol form ((')] can be obtained.
チアゾリジンジオン誘導体( I )は必要によ]?常法に従い酸または壌 基と反応させて境に導びくこともできる。  The thiazolidinedione derivative (I) is necessary]. It can also be reacted with an acid or a sulfonic group according to a conventional method and led to the boundary.
このようにして得られるチアゾリジンジォン绣 体およびその漥は公 知の分離精製手段たとえば濃繽, i s ,溶媒抽出,晶出,再桔晶, 溶,クロマトグラフィーなどによ]?単離精製することができる。  The thiazolidinedione thus obtained and the thiazolidinedione are obtained by known means of separation and purification, for example, by using concentrated pestle, is, solvent extraction, crystallization, recrystallization, dissolution, chromatography and the like. can do.
本旁明の化合物( I )およびその廑は哺乳勐物(たとえばマウス ,ィ ヌ , ネコ ,サ ,馬,人)に対し、優れた血中の锗,脂質低下作用を示 す。 また毒性は急性,亜急性毒性ともに低く、たとえば 5— { 4一〔 2 —ヒ ドロキシー 2— ( 6 ーメチ ー 2—ピリ ジ )エトキシ〕ぺンジ 1 } 一 2, 4一チアゾリジンジォン、 5一 { 4一〔 3—ヒ ドロキシー 2— ( 3—メチ 一 2—ピリ ジ )ブロポキシ〕ベンジ; }— 2, 4一チア ゾリジンジオン、 5— { 4一〔 2—( 5—ェチ 一 2—ビリ ジル)一 2 ーヒ ドロキシ〕ペンジ }一 2 · 4一チアゾリ ジンジオン、 5— { 4一 〔 2— ( 5—工チ ー 2—ビリ ジ )一 3— ドロキシブ口ホキシ〕ベ ンジ } 一 2 , 4一チアゾリ ジンジ *ン、 5— { 4一〔 2ーァセトキシ 一 2—( 6—メチ 一 2 -ビリ ジ ) ヱトキシ〕ベンジ }一 2, 4一 チアゾリ ジンジオン、 5— { 4一〔 3—ァセ トキシー 2—〔 5—ェチ 一 2—ビリ ジ ) ブロボキ^〕ペンジ } - 2 , 4一チアゾリ ジンジ才 ンは ずれもヲプ トにおける経口投与時の L D 50 は 5 0 0 Ο^/ ^以 上であった。 これらの点からチアゾリジンジオン綉導体( I )およびそ の塩は人の高脂血症 .糖尿病 よびそれらの合併症の治療に有用である ことが期待される。 投与方法は通常たとえば绽剤, カブセル剤,散剤, 顆粒剤 どとして経口的に用いられるが、場合によっては注射剤,座剤 ,ベレツトなどとして非经ロ的に 与することもできる。 溏尿病治療剤 として用 る場合は成人 1人につき通常 1日 α ο 5 J 〜i ^を柽 口的に、 (X 0 1 〜 1 o ^z^¾非経口的に、 また裹脂血症治療剤とし て用 る場合には成人 1人につき通常 1日 α 0 5 〜 1 0 を経口 的に、 α ο ι ^〜ι ο¾?ζ ^を非径ロ的に投与することができ、 この量 を 1日 1回または週に 2〜4回阇けつ的に投与するのが望ましい。 Compound (I) and its 廑 at the side of this report show excellent blood 锗 and lipid lowering effects on mammals (eg, mice, dogs, cats, cats, horses, humans). The toxicity is low in both acute and subacute toxicities. For example, 5- {4-1- [2-hydroxy-2- (6-methyl-2-pyridyl) ethoxy] benzene1} 12,4-thiazolidinedione, 5 1- {4-1- [3-hydroxy-2- (3-methyl-2-pyridyl) propoxy] benzy;} — 2,4-thiazolidinedione, 5 -— {4-1- [2 -— (5-ethyl-2-) (Viridyl) 1-2-hydroxy) benzene 1-2 · 4- thiazolidinedione, 5- {4- 1 [2- (5-tech 2-bilge) 1-3-doxyboxy oxy] benzene} 1 2 , 4-thiazolidinezine *, 5- {4- [2-acetoxy-12- (6-meth-2-1-)-ethoxy] benzy} -1,2-4-1 Thiazolidinedione, 5- (4- [3-acetoxy-2- (5-ethyl-1-bilidine) broboxy ^] penzi}-2,4,1 Oral administration of thiazolidinedinone in mice The LD 50 at that time was more than 500 Ο ^ / ^. From these points, it is expected that thiazolidinedione hypoconductor (I) and its salt are useful for treating hyperlipidemia and diabetes in humans and their complications. The method of administration is usually orally used, for example, as pills, capsules, powders, granules, etc., but in some cases it can be given non-periodically as injections, suppositories, or pellets. When used as an agent for treating syphilia, α ο 5 J ~ i ^ is usually administered orally (X 0 1 -1 o ^ z ^ ¾ parenterally, or lipolipidemic) per adult per day. When used as an agent for the treatment of infectious diseases, α55 to 10 can be administered orally and αοι ^ to iοο¾? Ζ ^ can be administered non-radially per adult per day. It is desirable to administer this amount once a day or two to four times a week.
本発明の原料化合物( π )はたとえばつぎのような方法によ]?製造す ることができる。  The starting compound (π) of the present invention can be produced, for example, by the following method.
I ) —殺式( π )中 ηが 0である化合物の製造  I) —Preparation of compound where η in formula (π) is 0
Figure imgf000011_0001
〔式中 R1, R2および Xは前記と同意義であ])、 R4'は R3 または R4 で示されるア^ 基と鬨意義であ]?、 は R5 で示される低級ア キ 基と同意羨である。 〕
Figure imgf000011_0001
[Wherein R 1, R 2 and X are as defined above der]), R 4 'A ^ groups and Toki significance der represented by R 3 or R 4] ?, lower represented by R 5 I agree with Akiki. ]
化合物( W)から化合物( V )への酸化反 は化合物 ( IV )に遢黢化 水素または有機過酸を反応させることによ!?容易に行なうことができる。 かかる有機過酸の例としては例えぱ過ギ酸,過齚黢,過トリプ ォロ静 ,過安息香酸, m—クロ 過安息香酸などがあげられ、本黢化反応は それ自体公知の一被的方法にしたがって行なうことができる。 化合物 The oxidation reaction of compound (W) to compound (V) is achieved by reacting compound (IV) with hydrogen peroxide or an organic peracid! ? Can be easily done. Examples of such organic peracids include, for example, formic acid, peroxide, pertriprostatic, perbenzoic acid, m-chloroperbenzoic acid, and the like. It can be performed according to the method. Compound
( V )から化^ 5 ( IT )へのァシ 化反応は化^ J ( V )にァシ 剤を 反応させることによ!?行 ¾われ、通常鲮無水物または鑀ハライドとをThe assimilation reaction from (V) to chemical ^ 5 (IT) is achieved by reacting the chemical with ^ J (V)! The reaction is usually performed with anhydrous or halide
80わ〜 150わに加熟することによ!?容易に行なわれる。化^ (H から化合输( IT)への加水分解反応は水酸化ナトリクムまたは水酸化力 リウムを用 る通常の方法によって行なうことができる。 80 ~ 150 by ripening! ? Easily done. The hydrolysis reaction from compound (H) to compound (IT) can be performed by a usual method using sodium hydroxide or potassium hydroxide.
8 ) 一般式( )中 nが 1である化合物の製造  8) Production of a compound in which n is 1 in the general formula ()
Η¾ι, Η - ¾ Rl"C o¾ Η¾ι, Η - ¾ Rl "C o¾
CB^® C¾0H  CB ^ ® C¾0H
(W) (¾)  (W) (¾)
Figure imgf000012_0001
Figure imgf000012_0001
O H 一 U— OH One U—
〔式中の各記号は前記と同意義〕  (Each symbol in the formula is as defined above)
化合物( w )から化合物 ( W )への反応は化^ g ( VI )と化合物 01〉 とを水素ィヒナトリウムの存在下に缩合することによ!)行なわれる。本反 応はジメチ ホ ムアミ ド, チトラ ドロフラン等の溶鑲中で一 1 0 t 〜2 0わで行 *うこ ができる。 つ で化合物(¾! )から化合物( ) への反応は化合物 ( W )を例えばパラジゥム炭素を触 として常法によ 接触還元することによ 行なわれる。 化合物( κ )から化合物 or) への反応は化合物( )をハロゲン化水素 .( H X )の存在下にジァゾ化 し、さらにアクリル酸またはそのエステ 類( X )を銅触媒(例、酸化 第一銅,酸化第二銷,壚化^一 ,塩化第二銅,臭化第一鋼,臭化第二 銅等)の 下に反応させる わゆる iieenrein arylati on 反応に よ D行なわれる。 化^^ (ΊΤ)から化合物(3T )への反応は化合 ¾8 (IT )をァシ 化することによ]?行なわれる。 この反応は前記化合物 ( V )をァシ 化する方法と同様にして行うことができる。  The reaction from compound (w) to compound (W) is achieved by combining compound (g) with compound 01> in the presence of sodium hydride! ) Done. This reaction can be carried out at a temperature of 10 t to 20 watts in a solution of dimethiformamide, titro- drofuran, or the like. The reaction from the compound (¾!) To the compound () is carried out by catalytic reduction of the compound (W) using, for example, palladium carbon as a catalyst in a conventional manner. In the reaction from compound (κ) to compound or), compound () is diazotized in the presence of hydrogen halide. (HX), and acrylic acid or its esthetics (X) is further converted to a copper catalyst (eg, oxidative oxidation). The reaction is carried out under the condition of copper, copper oxide, copper chloride, cupric chloride, ferrous bromide, cupric bromide, etc.). The reaction from the compound ^^ (ΊΤ) to the compound (3T) is performed by converting the compound ¾8 (IT) into a compound. This reaction can be carried out in the same manner as in the method for converting the compound (V) into a compound.
発明を実施するための最良の形^  BEST MODE FOR CARRYING OUT THE INVENTION ^
以下に実施例, ^考例および実 例を記載して本発明をよ 具体的に 説明するが、本発明はこれらに限定されるものではない。  Hereinafter, the present invention will be described in more detail with reference to Examples, Comparative Examples and Examples, but the present invention is not limited thereto.
実施例 1 Example 1
3— { 4一〔 2—ァセ トキシー 2—( 6一メチ 一 2ービリジ )ェ トキシ〕フヱ- }一 2—グロムブロピオン鲮メチル ( 2 ? ) ,チォ 尿素( 5 5 ) ,齚綾ナト リウム( 5 9 9 ) ,エタノー  3- {4- (2-acetoxy-2- (6-methyl-2-vinyl) ethoxy) phenyl} 2-grombropion-methyl (2?), Thiourea (55), sodium aya (5 9 9), Ethanor
の混合物を 4時間加熱逮流した後 6 N—塩酸( 3 0 » )を加え更に 1 6 時間加熱還流した。炭酸水素ナトリウム水溶液で中和後クロ口ホ ムで 抽出し、 クロ口ホ ム層は水^後乾燥( MgS04 )した。 溶煤を留去し、 残留物をシリ力ゲ ( 1 0 0 ? )を用 てカラムクロマトグラフィ一に After heating and arresting the mixture for 4 hours, 6N-hydrochloric acid (30 ») was added, and the mixture was refluxed for 16 hours. Extracted with neutralized after black hole Ho arm with aqueous sodium bicarbonate, the black hole ho beam layer was water ^ post-drying (MgS0 4). The soot is distilled off, and the residue is subjected to column chromatography using silica gel (100?).
. .. ""^f!PO 付し、ベンゼンーァセトン( 10 : 1 , )で溶出することによ]? 5一 { 4一〔 2ーヒドロキシー 2—( 6—メチ ー 2—ビリ ジ )エト キシ〕ペンジ }一 2 , 4—チアゾ1 ジンジオンを結晶として得 。叹 量 0L95 9. 群酸ェチ 一^ "キサンから再結晶することによ]?無色プリ ズム晶を得た。融 1 54 - 1 55 t . .. "" ^ f! PO And eluted with benzeneacetone (10: 1,)]? 5-1 {4- [2-hydroxy-2- (6-methyl-2-viridyl) ethoxy] pent}} 2,4 - give the thiazole 1 Jinjion as crystals. Mass 0L95 9. Recrystallization from xanthyl group [xan] ?? Colorless prism crystals were obtained.
元素分析値 C18HiaN204S として As Elemental analysis C 18 H ia N 2 0 4 S
計算值 ·· 32ϊ Η, 5. 06; Η, 7. 82  Calculation 值 ··· 32ϊ 5., 5.06; Η, 7. 82
実験値: C, 60· 53 ί Η, 5. 24; Ν, 7. 75  Experimental value: C, 60 · 53 ί 5., 5.24; Ν, 7.75
実旛例 2 Example 2
(1) 2—ブロム一 3— { 4—〔 3— tドロキシー 2—( 3—メチ 一 2 一ビリジ )プロホ。キシ〕フエ- }ブ口ビオン竣メチ ( 4.7 ) , チォ尿素( 8 75 ) , ^^ナト リウム( 943*1?) ,エタノー (50 ml )の混合物を 3時間加熱遠流した。 水で 釈し、炭^水素ナトリウム 水溶液で中和後 酸ェチ で抽出した。 ^綾ェチ 層を水洗後乾燥 ( gS04 )し、溶媒を留去することによ]) 5— { 4一〔 3—ヒドロキシ 一 2—( 3—メチ 一 2—ビリジ )ブロホ。キ^〕ペンジ }一 2—ィ ミノー 4一チアゾリジノンを結晶として得た。 収量 2·5 . これをク 口ホ ム一メタノー ^ら再結晶することによ]?無色ブリズム晶を得た < 融点 21 3 -2 1 4 t! (1) 2-bromo-1--3-4-droxy-2- (3-meth-1-2-viridity) proho. A mixture of methicone (4.7), thiourea (875), ^^ sodium (943 * 1?), And ethanol (50 ml) was heated and circulated for 3 hours. The mixture was diluted with water, neutralized with an aqueous solution of sodium hydrogencarbonate, and extracted with acid. ^ After washing twill E Ji layers dried (GS0 4), and by the fact the solvent was distilled off]) 5- {4 one [3-hydroxy-one 2- (3-methylcarbamoyl one 2- Biriji) Buroho.キ ^ ペ ン Penzi} -1 2-mino 4-thiazolidinone was obtained as crystals. Yield 2 · 5. This was recrystallized from Kouguchi-Methanol) to obtain a colorless bryth crystal <mp 21 3 -2 1 4 t!
元素分柝髖 C19H21N303S として Elemental 髖 髖 C 19 H 21 N 3 0 3 S
計算値: C,61. "; H, 5. 70; 31  Calculated: C, 61. "; H, 5.70; 31
実験僮: C, 61· 14; H, 5. 62; N.10.99  Experiment B: C, 61 · 14; H, 5.62; N.10.99
( (1)で得た 5一 { 4一〔 3—ヒ ドロキ^ー 2—( 3—メチ 一 2—ビ リジ )ブロボキシ〕ペンジ }一 2—イミノー 4一チアゾリジノン ( 2.3 ) ¾r2K一 ¾醆( 2 とエタノー ( 2 の潙合物に 溶解し、 4時間加熱逮流した。炭駿水素ナト リウム水溶液で中和後クロ 口ホ ムで抽出し、 ク 口ホ ム層は水洗後乾煉( MgS04 )した。 溶 媒を留去し 5— { 4一〔 3—ヒ ド口キシー 2—( 3—メチ 一 2—ビリ ジ ! )ブ ポキシ〕ベンジ }一 2 , 4一チアゾリジンジオンを結晶と して得た。収量 L ? . エタノー から再結晶し無色ブリズム晶を得た《 融点 1 8 2— 1 8 3わ (5-1 {4- [3-hydroxy-2- (3-methyl-1-bipyridine) broboxy] penti) obtained in (1)} 1-imino-4 thiazolidinone (2.3) ¾r2K-1 ¾ 醆 ( 2 and Ethanor (2 compound Dissolved and arrested for 4 hours heating. Extracted with neutralized after black hole Ho arm in TanShun hydrogen sodium solution, click port ho beam layer was washed with water dried practitioners (MgSO 4). The solvent was distilled off to obtain 5- {4- [3-hydroxy-2- (3-methyl-1-biphenyl!) Buoxy] benzyl]} 1,4-thiazolidinedione as crystals. . Yield L?. Recrystallization from ethanol gave colorless bristles.
元素分析 ϋ C19H2oR204S として As elemental analysis ϋ C 19 H 2 oR 2 04S
計算値: C, 61· 27; H, 5. 41; M, 7. 52  Calculated values: C, 61 · 27; H, 5.41; M, 7.52
実験値 ·· C,61. 57; H, 5. 49; N, 7. 74  Experimental value ··· C, 61. 57; H, 5.49; N, 7. 74
実施例 3 Example 3
3— { 4 -〔 2—ァセ トキシー 2—( 5—ヱチ 一 2—ビリジ A ェ トキシ〕フエ- }一 2—ブロムブ口ビ才ン綾メチノレ( 1 α 0 - ) , チ ォ尿素( 2·0 ) ,齚竣ナト リウム ( 2· 2 - )を 施例 1 と同様にエタ ノー〃中で反^させ、つ で加水分解することによ])、 5— { 4一〔 2 一 ( 5—ェチ ー 2一ピリ ジ )— 2—ヒ ドロキシエトキシ〕ベンジ }一 2 , 4—チアゾリジンジオンを結晶として得た。 収量 &2 9. 酔酸 ヱチ 一へキサンから再結晶、燕色ブリズム晶、 ,Ι 2 9— 1 30 元素分析値 C19fl20»204S として 3— {4- [2-Acetoxy 2 -— (5- ヱ 2--1-Bizyme A-ethoxy) fe-}-1-2-Brombu methine (1α0-), thiourea ( 2)), the completed sodium (2.2-) is reacted in ethanol as in Example 1 and then hydrolyzed. (5-Ethyl-2-pyridyl) -2-hydroxyethoxy] benzyl} 1,2,4-thiazolidinedione was obtained as crystals. Yield & 2 9. Recrystallization from peroxidic acid hexane, yellowish bristles,, Ι 29-1 30 Elemental analysis: C 19 fl20 »20 4 S
計算攛: C, 61· 27; H, 5. 41 ί Ν, 7. 52  Calculation 攛: C, 61 · 27; H, 5.41 ί 7., 7.52
実験値: C,61. 36; H, 5. 71 J H, 7. 08  Experimental value: C, 61.36; H, 5.71 J H, 7.08
実施例 4 Example 4
2—ブロム一 3— { 4一〔 2— ( 5—ェチ〃一 2—ビリヅ )一 3— ヒ ドロキシブ口ポキシ〕 フエ nル } ブ ビオン メチ ( 1 2.2 9 ) , チォ尿素( 2·2 ) ,齚醆ナト リ ウム ( 2·4 ) ,エタノー ( 1 0 0 )の混合物を 3時間加熱還流後 3 Μ—塩^ ( 1 0 を加え、 さら  2-brom-one 3— {4-1 (2- (5-ethyl-2-bi) -1-3—hydroxypoxy-hydroxyl) phenol} bubion meth (12.29), thiourea (2.2 ), Sodium (2.4), and ethanol (100) were heated to reflux for 3 hours, and 3 3-salt ^ (10 was added.
/ OMPI に 12時間加熱遽流した。攘縮後炭酸水素ナトリゥム水溶液で中和し、 酷酸ェチ で抽出した。酢鲮ェチ 層は水洗 ·乾像( MgS04 )後溶媒 ¾留去した。残留物をシリカゲ ( 20 0 - )を用 てクロマトグラフ ィ一に付し、ペンゼンーアセ トン( 5 : 1 , )で溶出する とに よ 5一 { 4一〔 2—( 5—ェチ 一 2—ピリジ )一 3—ヒドロキ^ ブロポキシ〕ベンジ^) - 2 , 4一チアゾリジンジオンを油状翁として 得た b収量 4·8 » ( 42.9 % ) . これをメタノー ( 1 5 i)に溶解し, ナト リゥムメチラート ( 2 8%メタノー 溶液 , 2.9? )を ¾ίえた後ェ チ uエーテ ( 1 50«f )を加えることによ]?ナトリケム ¾を結晶とし て得た。収量 4.8 ( 4 α7% ) . これをエタノー ーエチ エーチ から再結晶、無色ブリズム晶、 点 2 3 7— 2 3 8わ / OMPI Heated for 12 hours. After expulsion, the mixture was neutralized with an aqueous solution of sodium bicarbonate and extracted with severe acid. Su鲮E Ji layer was evaporated the solvent ¾ washed with water and Inuizo (MgSO 4). The residue was chromatographed using silica gel (200-) and eluted with pentane-acetone (5: 1,). Pyridi) -1-hydroxy ^ propoxy] benzi ^)-2,4-thiazolidinedione was obtained as an oily b yield 4.8 »(42.9%). This was dissolved in methanol (15i) to give sodium dimethyl methylate. (28% Methanol solution, 2.9?) Was added, followed by addition of ethanol (150 «f)] to obtain sodium chem. As crystals. Yield 4.8 (4 α7%). This was recrystallized from ethanol, colorless bristles, point 2 3 7—2 3 8
元素分析毓 C20H21½04S.Ha として As elemental析毓C 20 H 21 ½0 4 S.Ha
計算値: 58· 81; H, 5. 18; iT, 6.86  Calculated: 58 · 81; H, 5.18; iT, 6.86
実翁籤: 0,59. 06ϊ Η, 4.94; Μ, 6. 97  Real winner: 0,59. 06ϊ 4., 4.94; Μ, 6. 97
実旌例 5 Jeongjeon 5
5一 { 4一〔 2—ヒ ドロキシー 2一( 6—メチノレー 2—ピリ ジ )ェ トキ^〕ベンジ }一 2 , 4—チアゾリ ジンジオン( 3 5 0^ ) , ビリ ジン ( 5 i)及び無水酢酸 (
Figure imgf000016_0001
2日間放置後、 水中に注ぎ酴酸ェチルで抽出した。 酢酸ェチ 磨は水洙,乾澡 ( gS04) 後溶媒を留去した。残留物をシリ 力ゲ ( 2 0 ? )を用 るカラムク マトグラフィ一に付し、ベンゼンーァセ ト ン( 15 : l , V/7 )で溶 出することによ]? 5— { 4一〔 2—ァセトキシ一 2—( 6—メチ 一 2—ビリ ジル) エトキシ〕ペンジ } - 2 , 一チアゾリジンジオンを 油状物として得た。収量 360^( 89.8%) . I R ( Neat ) : 1740 , 1690 , 123 ΟΛ—1· N M R (CDC13) δ : 2.1
5-1 {4-1 (2-Hydroxy-21- (6-methynoleic 2-pyridyl) ethoxy)} benzyl-1,12-, 4-thiazolidinedione (3.50 ^), pyridine (5i) and acetic anhydride (
Figure imgf000016_0001
After standing for 2 days, the mixture was poured into water and extracted with ethyl acetate. Acetic E Ji grinding was distilled off Mizu洙, Inui澡(GS0 4) and the solvent. The residue was subjected to column chromatography using silica gel (20?) And eluted with benzene-aceton (15: l, V / 7).] 5— {4-1—2— Acetoxy-1- (6-methyl-2-viridyl) ethoxy] penti} -2,1-thiazolidinedione was obtained as an oil. . Yield 360 ^ (89.8%) IR ( Neat): 1740, 1690, 123 ΟΛ- 1 · NMR (CDC1 3) δ: 2.1
OMH  OMH
Vf?C> s ) , 2.51 ( 3H , s ) , 3.02 ( 1 H , dd , J l 4及び 9Hz ) , 3.41 ( 1Η , dd , J - 14及び 4Hz) , 437( 2H , d , J-5Hz) , 44 ( 1 H , dd ,; Γ» 9及び 4 Hz) , 6.13 ( lH , t , J-5Hz).a83(2 H. d . J-9Ha ) , 7.09( 2H f d , J=-9Hz ) , 7.0-7.7 (3fl , m). 実細 6 Vf? C> s), 2.51 (3H, s), 3.02 (1H, dd, Jl4 and 9Hz), 3.41 (1 ,, dd, J-14 and 4Hz), 437 (2H, d, J-5Hz), 44 ( 1 H, dd,;. Γ »9 and 4 Hz), 6.13 (lH, t, J-5Hz) .a83 (2 H. d J-9Ha), 7.09 (2H f d, J = -9Hz), 7.0 -7.7 (3fl, m).
5— { 4一〔 2—( 5—ェチ 一 2—ビリ ジ ) 一 3—ヒ ドロキシブ ロボキ 〕ペンジル } - 2 , 4一チアゾリ ジンジオンナト リゥム (  5— {4—1—2— (5—2—1—2—1) —3—Hydroxyb loxo) penzil} —2,4,1—thiazolidinedionnatum (
408 , ビリ ジン( 1 0 ,無水醉鲮( 0.1 の混合物を室 温で 8時間かき混ぜた後水中に注ぎ、 ^酸ェチルで抽出した。 群鲮ェチ 層は水洗,乾燥( MgS04 )後溶媒を留去し、残留物をシリ力ゲ 408, kink Gin (1 0, poured into water was stirred for 8 hours a mixture of anhydrous醉鲮(0.1 at room temperature, and extracted with ^ acid Echiru. Gun鲮E Chi layer was washed with water, dried (MgSO 4) the solvent And the residue is removed
( 2 0 9 )を用いるカラムクロマトグラフィーに付した。 ベンゼンーァ セ ト ン( 1 0 : 1 · Vノ V )で溶出し、 5— { 4一〔 3—ァセ トキ^一 2 - ( 5ーェチ 一 2—ビリ ジ )ブロ キシ〕ペンジ }一 2, 4一 チアゾリジンジ才ンを油状物として得た。 収盧 35 0»y ( 8 L 8% ) . I R (Neat): 1740 , 1690 , 12 Z0c*^1 o N M R (CDCl3) : 1.24( 3H , t , J-7Hz ) , 2.00 ( 3H , s ) , 2.64 ( 2H , q , J = 7Hz), 03( lH , dd , J = l 4i¾>'9 H z ) , 3.45 ( 1 H , d d , J=l 4及び 9 Hz ) , 3.60( lH , m) , 4.3l ( 2H t d t J-5Hz ) , 4.47 ( 1H , dd , J = 9及び 4 Hz) , 4.55( 2H , d , J = 5Hz) . Column chromatography using (209). Elution with benzene-aceton (10: 1 V-V), and 5- {4- [3-acetoxy ^-1- (5-ethyl-2-bi) oxy) pentoxide} 41 The thiazolidinediene was obtained as an oil. IR (Neat): 1740, 1690, 12 Z0c * ^ 1 o NMR (CDCl 3 ): 1.24 (3H, t, J-7Hz), 2.00 (3H, s) ), 2.64 (2H, q, J = 7 Hz), 03 (lH, dd, J = l 4i¾>'9 H z), 3.45 (1 H, dd, J = l 4 and 9 Hz), 3.60 (lH, m), 4.3 l (2H t d t J-5Hz), 4.47 (1H, dd, J = 9 and 4 Hz), 4.55 (2H, d, J = 5 Hz).
6.80( 2H . d , J = 9Hz ) , 7.10( 2H , d t J = 9Hz) , 7.20 ( 1 H ,d , J-8H2) .7.48 ( lH , dd , J =«8及び 2 Hz ) , &42 ( 1 H , d , J = 2Hzs ) 実施例 7 錠剤の製造例 6.80 (2H. D, J = 9Hz), 7.10 (2H, d t J = 9Hz), 7.20 (1 H, d, J-8H2) .7.48 (lH, dd, J = «8 and 2 Hz), & 42 (1H, d, J = 2Hzs) Example 7 Tablet Production Example
(1) 5— { 4一〔 2—( 5—ェチ 一 2—ビリジ )エトキ 〕ペン  (1) 5— {4 1 [2— (5—et 1—2—bilge) ethoxy] pen
OMPI OMPI
' 、 VIPO― ジ t }一 2 , 4—チアゾリ ジンジ才ン 1 0 0 ?', VIPO- 1 2, 4-thiazolidine 1 0 0?
(^ 乳 糖 50(^ Lactose 50
(3) トゥ *口 3 ^でんぷん 1 5 9(3) To * mouth 3 ^ starch 1 5 9
(4) カルボキシメチ セ σ—スカ シクム 449 (5) ステアリ ン鲮マグネグタム 1 9 (4) Carboxymethyl sigma-squash 449 (5) Stearyl magnetatum 1 9
10 00錠 2 1 0 ? (1) , (2),(3)の全羹及び 30 9の (4)を水で練合し、真空乾燥後製粒を行 ¾う。 この製粒寧に 1 4 <θ(4)及び 1 3¾5)を混合し、打錠機で锭剤と することによ D、 1錠当 0 を含有する直径 8∞の锭剤  1100 tablets 2 10? Knead all of the yokan (1), (2) and (3) and 309 (4) with water, dry in vacuum, and granulate. By mixing 14 <θ (4) and 13¾5) into the granules, the mixture is made into a tablet by a tableting machine. D. A tablet with a diameter of 8∞ containing 0 per tablet
1 0 00個を製造する。  100 pieces are manufactured.
参考例 1 Reference example 1
(1) 2—ブロム一 3— { 4一〔 2—( 6—メチ 一 2—ビリ ジ A エト キシ〕フエ- ブ口ビオン酸メチ ( 1 α 0 ^ )のメタノー ( loo 羃 )溶液に m—クロ 過安息香鲮(含量 7 0% . 7.1 f )を加え 30分 間加熱還流した。 チォ ¾竣ナトリゥム水溶液を加えて遢 iの鈹化剤を分 解後、水を加え醉酸ェチ で抽出した 0 齚酸ェチ は水, 2 一水酸 化カリウム ,水の瞩に洗净し乾燥( MgS04 )後溶緙を留去し、 2—ブ ロム一 3— { 4 - 2— ( 6ーメチ ー 2—ビリ ジ )ェトキシ〕フエ(1) 2-Bromo-3- (4- (2- (6-Meth-2-2-Viridyl A ethoxy))-Five Methyl Bionate (1α0 ^) in methanol solution —Chlorobenzoic acid (content 70%; 7.1 f) was added and the mixture was heated under reflux for 30 minutes, and then an aqueous solution of sodium was added to decompose the agent for i), water was added, and water was added. extracted 0齚酸E Ji water, potassium 2 Ichimizusan reduction, was distilled off and lavage of water瞩dried (MgSO 4) after溶緙, 2 Bed Lom one 3- {4 - 2- ( 6-Methyl 2-Bridge) Ethoxy] Hue
- } ブ ビオン黢メチ ir一才キシドの粗油状物を得た。 収量 -} Bubion Methi ir A crude oil of one-year-old oxide was obtained. Yield
10.1 9. I R (Neat): 1740 , 1250««一1 10.1 9. IR (Neat): 1740 , 1250 «« one 1
(2) (1)で得た 2—ブロム一 3— { 4一〔 2—( 6—メチルー 2—ビリジ )エトキシ〕フェ二 }ブロビ才ン酸メチ Ν—ォキシド ( 1 αΐ (2) 2-bromo-1-3- [4- [2- (6-methyl-2-viridyl) ethoxy] phene} obtained in (1) methoxide bromide (1αΐ)
9 ) ,無水酵酸( 5 0 W )の混合物を 1 1 0 で 1時間加^滅圧下に 濃縮し、残留物をシリカゲル( 20 09 )を用 てカラムクロマトグラ フィ一に付し 。 ベンゼンーァセ ト ン( 50 ·· 1 , Υ/Τ )で溶出する ことによ 、 3— { 4一〔 2—ァセトキ ー 2—( 6—メチ 一 2—ビ リジ )ェトキシ〕フエ-〃 }一 2—ブロムブ ビオン酸メチ を油状 物として得 β収量 3·3? · I R (Neat): 174 1 (broad ). N UR (CDC13)^: 2.13( 3H f s) , 2.53(3H s) ,ai4( lH , dd , J =l 4及び 7 Hz) ,a40( lH , dd , J=-l 4及び 7 Hz ) , ¾70( 3H , a ) , 4.2— 4.5 ( 3 Η , a ) , 6.15 ( 1 Η , t , J = 6 Η ζ ) , 6.8-7.6 ( 7Η , m ) 9) The mixture of acetic anhydride (50 W) was concentrated at 110 under reduced pressure for 1 hour, and the residue was subjected to column chromatography using silica gel (2010). Elution with benzene-aceton (50 ·· 1, Υ / Τ) Thus, 3- {4- [2-acetoxy-2- (6-methyl-2-vinylidoxy) ethoxy] phen-II} -1-bromobutionate was obtained as an oil, and the β yield was 3.3? IR (Neat): 174 1 (broad) .N UR (CDC1 3 ) ^: 2.13 (3H fs ), 2.53 (3Hs), ai4 (lH, dd, J = l4 and 7 Hz), a40 ( lH, dd, J = -l 4 and 7 Hz), ¾70 (3H, a), 4.2--4.5 (3Η, a), 6.15 (1Η, t, J = 6Η), 6.8-7.6 (7Η) , m)
參考例 2  Reference Example 2
(1) 2—( 3—メチ 一 2一ビリジ )一 1 · 3—ブロビレングリコー /^( 1 Q.Q 9 )及び ρ—ブ ォロニトロペンゼン( & 4 5 f )のジメチ ルホ ムアミド( 1 00»/) 液に、氷冷下かき混ぜながら 60%油性 水素化ナト リウム ( 2·8 9 )を少量ずつ加えた。 1時間水冷下にかき混 ぜた後、 反応液を氷水中に注ぎ、酢钹ェチ で抽出した。 酢酸ェチル虜 は水洗,乾燥(MgS04)後潘媒を留去し、残留物をシ.リ力ゲ ( 2ひ 0 9 )を用 てカラムクロマ トグラフィ一に付した。 シク口へキサンー齚 ェチ ( 3 : 1 » /Ί )で溶出することによ]) 4一〔 3—ヒドロキ シー 2—( 3—メチルー 2—ビリ ジ ) ブロホ。キ 〕 - ト口ベンゼンを 結晶として得た。 収量 ¾6 9. 齚菠ェチル一》 ^キサンから再結晶するこ とによ 無色ブリズム晶を得た。 点 1 3 5— 1 3 6 (1) 2- (3-Methyl-2-1-bilidi) -1 · 3-Brobilenglycol / ^ (1QQ9) and dimethylformamide (100) of ρ-boronitropentene (& 45f) »/) 60% oily sodium hydride (2.89) was added little by little to the liquid while stirring under ice cooling. After stirring under water cooling for 1 hour, the reaction solution was poured into ice water and extracted with vinegar. Acetate Echiru prisoner is washed with water, dried was distilled off (MgSO 4) After Ban medium, the residue is. Subjected to Karamukuroma Togurafi one Te use the Li force gain (2 Fei 0-9). It is eluted with a hexahedral hexane (3: 1 »/ Ί)]) 4- [3-hydroxy 2- (3-methyl-2-bilidine) bropho. G)-benzene was obtained as crystals. Yield ¾6 9. 齚 ェ ェ》 ^ ^ ^ Colorless bristles were obtained by recrystallization from xane. Points 1 3 5— 1 3 6
元素分析籤 Ci5Hi6N204 として Elemental analysis as Ci 5 Hi6N204
計真镇: C, 62· 49; H, 5. 59; N, 9. 72  Total: C, 62 · 49; H, 5.59; N, 9.72
実験值: C, 62· 60; H, 5. 69; N, 9. 93  Experiment II: C, 62 · 60; H, 5.69; N, 9.93
(2) (1)で得た 4一〔 3—ヒドロキシー 2—( 3—メチ 一 2—ビリジ )ブロボキシ〕 -トロベンゼン( ao 9 )をメタノール( 1 0 に 溶解し、 1 0%パラジウム炭素を用いて常温,常圧で接敏還元した。 触 、 ,ίΗ γ> ,, リ 媒をろ去後溶 atを留去した。つぎに残留物をメタノ一 ( sow) ,ァ セトン( 20 W )及び 47 %臭化水素酸水溶液( 2 L5 9 )の混合物に 溶解し、氷冷下に 5 t 下の温度で亜硝黢ナトリウム ( 4 - )の水 ( 5» 溶液を滴下し、 さらに 5 で 30分 (Mかき混ぜ 。 れにァク リ 酸メチ ( 1 5.9 - )を加え、約 40わに加温し、激しくかき混ぜ ¾がら酸化第一銅 ( 7.0? )を少量ずつ加えた。反応温度を 45 tは下 で約 3時間、窒素の尧生が止まるまでかき混ぜた。反応液を減圧下に濃 縮し、澳アンモ ァ水でア 力 1/性とし 7t後齚酸ェチ で抽出した。酷 駿ェチ 層は水洗 ·乾燥( MgS04 )後溶媒を留去し、残留物をシリ方 ゲ ( 230 ? )を用 てカヲムクロマトグラフィ一に付した。 ェチ エーテ 一へキサン一トリェチノレアミン( 7 5 : 25 : 1 , 7/T )で 溶出することによ 2—ブロム一 3— { 4一〔 3 -ヒドロキシー 2—( 3ーメチ ー 2—ピリ ジ ) ブロホ 3キシ〕 フエ- } プロビオン竣メチ ルを油状物として得 7¾1。収量 4.8 9. I R (Neat): 3370 , 1735 cm-1. N il R (CDC13)3: 2·35 ( 3H , s ) , i9— 3·4( 2H , a ) , 3.3-3.7 ( 1Η , a ) , 3·63 ( 3Η , a ) , 3>9 ( 1 Η, broad ) , 4.07 (2H , d t J»3Hz ) t 4.1-4-6( 3H . a) , 6.76 ( 2H , d , J' = 9 Hz ) , 7.04 ( 2H . d , J = 9Hz ) f 7.3~7.6( 2H , a) ,a30 ( lH , dd , J«5及び 2Hz ) (2) Dissolve the 4- [3-hydroxy-2- (3-methyl-2-viridi) broboxy] -trobenzene (ao9) obtained in (1) in methanol (10) and add 10% palladium carbon. The contact reduction was carried out at normal temperature and pressure at room temperature. After removing the medium by filtration, the dissolved at was distilled off. Next, the residue was dissolved in a mixture of methanol (acetone), acetone (20 W) and a 47% aqueous solution of hydrobromic acid (2 L59), and sodium nitrite was added at a temperature of 5 t under ice cooling. Add a solution of (4-) in water (5 »), add 5 more for 30 minutes (M. Stir. Add methacrylate (15.9-) to the mixture, warm to about 40, and stir vigorously. Cuprous oxide (7.0?) Was added in small portions, and the mixture was stirred under a reaction temperature of 45 t for about 3 hours until nitrogen generation ceased. in and extracted with an a force 1 / resistance 7t after齚酸E Ji. severe Shun E Chi layer was distilled off washed with water and dried (MgSO 4) the solvent, Te use the residue by silica lateral gate (230?) Elution with ethyl acetate-hexane-triethynoleamine (75: 25: 1,7 / T) was performed by elution with 2-bromo-1--3- (4- [3-hydroxy- 2— ( .. 3 Mechi-2-pyridinium) Buroho 3 carboxy] Hue -} Purobion竣give the methylation as an oil 7¾1 Yield 4.8 9. IR (Neat): 3370 , 1735 cm- 1 N il R (CDC1 3) 3 : 235 (3H, s), i9— 34 (2H, a), 3.3-3.7 (1Η, a), 363 (3Η, a), 3> 9 (1 (, broad), 4.07 (2H, d t J »3Hz) t 4.1-4-6 (3H .a), 6.76 (2H, d, J '= 9 Hz), 7.04 (2H .d, J = 9Hz) f 7.3 ~ 7.6 (2H , a), a30 (lH, dd, J «5 and 2Hz)
参考例 3 Reference example 3
(1) 2—ブロム一 3— { 4一〔 2 - ( 5—ェチ 一 2—ビリジ )エト キシ〕 フエ- } ブロビオン羧メチル( 1 & 5 )を参考例 1一 (1)と同 様に at—クロ 過安息香酸で酸化し 2—ブロム一 3— { 4一〔 2—( 5 一ェチ 一 2—ビリ ジ )ヱトキ 〕フエ = } ブロビォン酸メチ ϊί一オキ^ドを油状物として得た。収量 1 a 2 . (2) (1)で得た 2—ブロム一 3— { 4一〔 2—( 5—ェチ 一 2—ビリジ(1) 2-Bromo-3- (4- [2- (5-eth-2-1-2-ethoxy) ethoxy] fu-} Brobion-methyl (1 & 5) is the same as Reference Example 1-1 (1) Oxidized with at-chloro perbenzoic acid and oxidized with 2-bromo-1-benzoic acid 2- 2-bromo- (4- (5-ethyl-1-2-bis) ethoxy) fu = = methionic brobionic acid as an oil Obtained. Yield 1a 2. (2) 2-Brom-1 3- (4-1) obtained in (1) [2- (5-Et-1-2-Viridi)
/« )エトキシ〕フエ- }ブロビオン饞メチ Mーォキ yド( 1 0/ «) Ethoxy] Hue-} Brobion
9 )を參考例 1一 (2)と同様に無水醉黢と反応させ、生成物を リカゲ カラムクロマトグラフィーで精製する とによ]、 3— { 4一〔 2—ァ セトキシー 2— ( 5—ェチ 一 2ービリジ )エトキシ〕フエ-; — 2—ブロムブロビオン酸メチ を油状物として得た。収量 1 0.29. I R ( eat): 1730ο»"1. M M R (CDC13)^: L23 ( 3H , t . J = 7Hz ) , 2.13 ( 3H , s ) , 2.66 ( 2H , q , J»7Hz ) , 3.12(l H , dd , J-l 4¾2>*7Ηζ ) , 3.40( l H ,dd , J«l 4及び 7 Hz ) , 3.70( 3H , s ) t .33( lH . t , J-7Hz ) t 40(2H, d , J- 5Hz ) , 6.l 7( lH , t f J = 5Hz) , 6.83 ( 2H , d , J»9Ha ) , 7.1 l ( 2H , d t J = 9Hz) , 7.33( lH , d , J = 8Hz ) , 7.54( l H, d d , J - 8及び 2 H z ) , & 43 ( 1 H , d , 3" = 2 H z ) Refer to 9) Reference Example 11 As in (2), react with anhydrous alcohol and purify the product by lizard column chromatography.], 3— {4-1 (2-acetoxy 2-— (5- Methyl 2-biradine) ethoxy] phen-; meth-2-bromobrobionate was obtained as an oil. . Yield 1 0.29 IR (eat):. 1730ο »" 1 MMR (CDC1 3) ^: L23 (. 3H, t J = 7Hz), 2.13 (3H, s), 2.66 (2H, q, J »7Hz), 3.12 (l H, dd, Jl 4¾2> * 7Ηζ), 3.40 (l H, dd, J «l 4 and 7 Hz), 3.70 (3H, s) t .33 (lH. t, J-7Hz) t 40 (2H, d, J- 5Hz) , 6.l 7 (lH, t f J = 5Hz), 6.83 (2H, d, J »9Ha), 7.1 l (2H, d t J = 9Hz), 7.33 (lH , d, J = 8Hz), 7.54 (lH, dd, J-8 and 2Hz), & 43 (1H, d, 3 "= 2Hz)
寥考例 4 Litigation example 4
参考例 2と同様にしてつぎの化合物を得た。  The following compound was obtained in the same manner as in Reference Example 2.
(1) 4—〔 2—( 5—ェチ 一 2—ピリジ A — 3—ヒ ドロキシブロ キシ〕 -ト σベンゼン:油状物, ; E R (Heat) : 3250 , 1330«" N MR (CDC13)3: L23 ( 3H , t f J = 7Hz ) , 2.63( 2H , q » J »7Hz ) , 3.35 ( l H , m) , 4.10( 2H , d , J=»4Hz ) , .50( 3H , m) , 6.93( 2H , d f
Figure imgf000021_0001
8H¾) ,
(1) 4- [2- (5-E Ji one 2-pyrid-A - 3- arsenide Dorokishiburo carboxy] - DOO σ benzene oil,; ER (Heat): 3250 , 1330 «" N MR (CDC1 3) 3: L23 (3H, t f J = 7Hz), 2.63 (2H, q »J» 7Hz), 3.35 (l H, m), 4.10 (2H, d, J = »4Hz), .50 (3H, m ), 6.93 (2H, d f
Figure imgf000021_0001
8H¾),
7.51 ( 1 H . d d . = 82¾ *2Ηζ ) , &13( 2H, d , J»9Hz) , & 35 ( 1H , d . J»2Hz )  7.51 (1 H .d d. = 82¾ * 2Ηζ), & 13 (2H, d, J »9Hz), & 35 (1H, d.J» 2Hz)
(2) 2—ブロム一 3— { 4一〔 2—( 5—ェチ 一 2—ビリジ )一 3 一ヒドロキシブ口ホ。キ 〕フエ- }プロビ才ン酸メチ : 油状物. I R (Neat): 3300 , 1730»"1. N R (CDC1S) ^: L23 (3H , t ,J-7Hz) , 2.62( 2H , q »J-7Hz) f 3«0〜 5( 3H , m) , 3.68(3H » s) , 09(2H , d f J = 4Hs) r 2— 6 ( 3H , m) , 6.7—7.6 (6H , a) , &35 ( 1H d, J-2Hz ) (2) 2-Bromo-3- (4- (2- (5-Et-1-2-Viridi) -13-hydroxyl). G) -Fe-Methyl methacrylate: oil. IR (Neat): 3300, 1730 »" 1. NR (CDC1 S ) ^: L23 (3H, t, J-7Hz), 2.62 (2H, q »J-7Hz) f 3« 0 ~ 5 (3H, m), 3.68 (3H »s), 09 (2H, d f J = 4Hs) r 2-6 (3H, m), 6.7-7.6 (6H, a), & 35 (1H d, J-2Hz)
マウスにおける血镶および脂質低下作用 被検化合物を粉末飼料( C E— 2,日本クレア )に ( 005%混合し, K K A マウス(雄性, 8〜: L 0週令, 1 5匹)に自由に 4日間孚ぇ た。 この間水は自由に与えた。血液を ¾静臃そうから採取し、血瑭镶 をグ コースォキ ^ダーゼ法によ 、また血漿トリグリセライド値は瘻 素法によ!)生成するグリセロー を Cleantech TG— Sキッ ト(ャトロ ン)を用いて定量することによ]? ^ぞれ測定した。それぞれの値は、 薬物非投与群に対する低下率( )で示した。 化 合 物 血糙低下作用 脂質佳下作用  Hypoglycemic and lipid-lowering effects in mice The test compound was mixed with powdered feed (CE-2, CLEA Japan) (005%) and freely mixed with KKA mice (male, 8-: L0 week old, 15 mice). Water was given ad libitum during this period, blood was collected from the bacterium, blood was collected by the glucose assay, and plasma triglyceride levels were determined by the fistula method!) By using Cleantech TG-S kit (Chatron)]. Each value was shown as a reduction rate () with respect to the drug non-administration group. Compound Hypoglycemic action Lipid-lowering action
(実施例 ) (%)  (Example ) (%)
45 47  45 47
2 22  2 22
3 32 35  3 32 35
4 45 38  4 45 38
産業上の利用町能性 Industrial use
本発明に係る新規チアゾリジンジォン誘導体 ( I )はすぐれた血 及 び血中脂質返下作用を有し、馕尿病治療剤,高脂血症治療剤など医薬品 等として有用である。  The novel thiazolidinedione derivative (I) according to the present invention has an excellent blood and blood lipid-returning effect, and is useful as a pharmaceutical such as a therapeutic agent for diuresis and a therapeutic agent for hyperlipidemia.

Claims

請 求 の 範 囲  The scope of the claims
L —般式  L — general formula
Figure imgf000023_0001
Figure imgf000023_0001
0  0
〔式中、 R1 , R2は同一または異¾つて水素または低級ア キ 基を、 R3 は水素またはァシ 基を、 nは 0または 1を示す。 〕で表わされる チアゾリジンジォン ϋ導体またはその ¾ [Wherein, R 1 and R 2 are the same or different and each represents hydrogen or a lower alkyl group; R 3 represents hydrogen or an acyl group; and n represents 0 or 1. Thiazolidinedione ϋ conductor or its ¾
Figure imgf000023_0002
Figure imgf000023_0002
〔式中、 R1 , R2は同一または異なって水素または低級ア キ 基を、 R4 は水素またはァシ 基を、 R5 は水素または低級ァ〃キ 基を、 X はハロゲン原子を、 nは 0または 1をそれぞれ示す。 〕で表わされる化 合物 チォ尿素とを反応させて一殺式 [In the formula, R 1 and R 2 are the same or different and each represents hydrogen or a lower alkyl group, R 4 represents a hydrogen or an acyl group, R 5 represents a hydrogen or a lower alkyl group, X represents a halogen atom, n represents 0 or 1, respectively. Thiourea is reacted with the compound represented by
Figure imgf000023_0003
Figure imgf000023_0003
〔式中の各 Ϊ3号は前記と同意義である。 〕で表わされる化合物を得、つ いでこれを加水分解し、必要によ])さらにァ 化することを特 とす る一殺式  [Each of the formulas in the formula is as defined above. ], Which is then hydrolyzed and, if necessary, is converted to a further compound.
O PI CH2-CH一 C=-0 O PI CH 2 -CH-1 C = -0
i r  i r
(CH2)n S NH (CH 2 ) n S NH
 ヽ
OR3 II OR 3 II
0  0
〔式中、 R1 , および nは前記と同意義であ I R3 は水素またはァ シ 基を示す。 〕で表わされるチアゾリ ^ンジオン^ 体の製造法 3. —赋 [Wherein, R 1 and n are as defined above, and I R3 represents hydrogen or an acyl group. Method for producing thiazoline ^^^^^-
Figure imgf000024_0001
Figure imgf000024_0001
〔式中、 R1 , R2は同一または異¾つて水素または低級ア キ 基を、 R3 は水素またはァシ 基を、 nは 0または 1を示す。 〕で表わされる チアゾリジンジオン誘導体またはその塩を含んで る 楽組成物 [Wherein, R 1 and R 2 are the same or different and each represents hydrogen or a lower alkyl group; R 3 represents hydrogen or an acyl group; and n represents 0 or 1. A composition comprising a thiazolidinedione derivative or a salt thereof represented by the formula:
PCT/JP1984/000117 1984-03-21 1984-03-21 Thiazolidinedione derivatives, process for their preparation, and medicinal composition containing same WO1985004170A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PCT/JP1984/000117 WO1985004170A1 (en) 1984-03-21 1984-03-21 Thiazolidinedione derivatives, process for their preparation, and medicinal composition containing same
PCT/JP1984/000445 WO1985004171A1 (en) 1984-03-21 1984-09-14 Thiazolidinedione derivatives, process for their preparation, and medicinal compositions containing same
US06/711,536 US4582839A (en) 1984-03-21 1984-09-21 2,4-thiazolidinediones
JP60041584A JPS60208980A (en) 1984-03-21 1985-03-01 Thiazolidinon derivative, preparation thereof and pharmaceutical composition containing same
EP85301895A EP0155845A1 (en) 1984-03-21 1985-03-19 Thiazolidinedione derivatives, their production and use
CA000476976A CA1263961A (en) 1984-03-21 1985-03-20 5-¬4-(2 pyridylalkoxy)benzyl|-2,4- thiazolidinedione compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP1984/000117 WO1985004170A1 (en) 1984-03-21 1984-03-21 Thiazolidinedione derivatives, process for their preparation, and medicinal composition containing same

Publications (1)

Publication Number Publication Date
WO1985004170A1 true WO1985004170A1 (en) 1985-09-26

Family

ID=13818276

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP1984/000117 WO1985004170A1 (en) 1984-03-21 1984-03-21 Thiazolidinedione derivatives, process for their preparation, and medicinal composition containing same
PCT/JP1984/000445 WO1985004171A1 (en) 1984-03-21 1984-09-14 Thiazolidinedione derivatives, process for their preparation, and medicinal compositions containing same

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/JP1984/000445 WO1985004171A1 (en) 1984-03-21 1984-09-14 Thiazolidinedione derivatives, process for their preparation, and medicinal compositions containing same

Country Status (2)

Country Link
JP (1) JPS60208980A (en)
WO (2) WO1985004170A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010105048A1 (en) * 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues
US8912335B2 (en) 2009-12-15 2014-12-16 Metabolic Solutions Development Company, Llc PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891216A (en) * 1987-04-14 1990-01-02 Alcide Corporation Disinfecting compositions and methods therefor
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
FR2680512B1 (en) * 1991-08-20 1995-01-20 Adir NOVEL 2,4-THIAZOLIDINEDIONE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AU2007227552A1 (en) * 2006-03-16 2007-09-27 Metabolic Solutions Development Company Combination therapies of thiazolidinedione analogues and glucocorticoid agonists
WO2007109024A2 (en) * 2006-03-16 2007-09-27 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
PL2001469T3 (en) * 2006-03-16 2012-10-31 Metabolic Solutions Dev Co Llc Thiazolidinedione analogues

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, Vol. 98, No. 15, Abstract No. 98 : 125945S; & Chem. Pharm. Bull. 1982, 30(10), 3580-600 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010105048A1 (en) * 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues
US8912335B2 (en) 2009-12-15 2014-12-16 Metabolic Solutions Development Company, Llc PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases
US9126959B2 (en) 2009-12-15 2015-09-08 Metabolic Solutions Development Company, Llc PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases

Also Published As

Publication number Publication date
JPS60208980A (en) 1985-10-21
WO1985004171A1 (en) 1985-09-26
JPH0570633B2 (en) 1993-10-05

Similar Documents

Publication Publication Date Title
US4582839A (en) 2,4-thiazolidinediones
EP0177353B1 (en) Thiazolidinedione derivatives, their production and use
EP0579733B1 (en) Thiazolidinedione derivatives, production and use thereof
KR910000723B1 (en) Hypoglycemic thiazolidinedion derivatives
US5441971A (en) Thiazolidinedione derivatives, production and use thereof
JPH06779B2 (en) Thiazolidione derivative and pharmaceutical composition comprising the same
CZ242590A3 (en) Substituted n-(aryloxyalkyl)heteroarylpiperidines and -heteroarylpiperazines, process of their preparation intermediate used in the process, pharmaceutical preparation and use
JPH07267964A (en) New n-heterocyclic thienothiazinecarboxamide, its productionand its use
WO1981001554A1 (en) Isoxazole derivatives
JPH0782269A (en) Thiazolidinedione derivative, its production and pharmaceutical composition containing the derivative
JPS58501722A (en) [1↓-(2↓-benzoxazolyl)hydrazino]alkylnitrile derivative
WO1985004170A1 (en) Thiazolidinedione derivatives, process for their preparation, and medicinal composition containing same
EP0508740B1 (en) Thiazolidinedione derivatives, their production and their use
JPH10237049A (en) Benzisoxazole derivative
JPH044312B2 (en)
EP1742927B1 (en) Butanoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications threreof
WO1986002073A1 (en) Thiazolidinedione derivatives, process for their preparation, and pharmaceutical composition containing same
JPS6257635B2 (en)
JPS6019317B2 (en) Thienothiazine derivative and method for producing the same
JPS5980687A (en) Novel derivative of oxazinobenzothiazine-6,6- dioxide, manufacture and use as drug
NO162462B (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 5- (2-ALCOXYPHENYL) -TIAZOLIDE INDION DERIVATIVES.
WO1990011278A1 (en) Thiazole compounds and applications thereof
CS248726B2 (en) Production method of ether precursors of the oxicams with antiinflammation effect
JP2001518068A (en) Novel heterocyclic compounds having anti-diabetic, hyperlipidemic and anti-hypertensive properties, a process for their preparation and pharmaceutical compositions containing them
JPH0125742B2 (en)

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): MC US